{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:59:46Z","timestamp":1787497186578,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As indications for sodium-glucose co-transporter-2 inhibitors (SGLT2i) are expanding, a growing number of older adults have become candidates for treatment. We studied the safety profile of SGLT2i among older adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, pharmacovigilance study of the FDA\u2019s global database of safety reports. To assess reporting of pre-specified adverse events following SGLT2i among adults (&lt;\u200975\u00a0years) and older adults (\u2265\u200975), we performed a disproportionality analysis using the sex-adjusted reporting odds ratio (adj.ROR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified safety reports of 129,795 patients who received non-insulin anti-diabetic drugs (NIAD), including 24,253 who were treated with SGLT2i (median age 60 [IQR: 51\u201368] years, 2,339 [9.6%] aged\u2009\u2265\u200975\u00a0years). Compared to other NIAD, SGLT2i were significantly associated with amputations (adj.ROR\u2009=\u2009355.1 [95%CI: 258.8\u2009\u2212\u2009487.3] vs adj.ROR\u2009=\u2009250.2 [79.3\u2009\u2212\u2009789.5]), Fournier gangrene (adj.ROR\u2009=\u200945.0 [34.5\u2009\u2212\u200958.8] vs adj.ROR\u2009=\u200988.0 [27.0\u2009\u2212\u2009286.6]), diabetic ketoacidosis (adj.ROR\u2009=\u200932.3 [30.0\u2009\u2212\u200934.8] vs adj.ROR\u2009=\u200923.3 [19.2\u2009\u2212\u200928.3]), genitourinary infections (adj.ROR\u2009=\u200910.3 [9.4\u2009\u2212\u200911.2] vs adj.ROR\u2009=\u20098.6 [7.2\u2009\u2212\u200910.3]), nocturia (adj.ROR\u2009=\u20095.5 [3.7\u2009\u2212\u20098.2] vs adj.ROR\u2009=\u20096.7 [2.8\u2009\u2212\u200915.7]), dehydration (adj.ROR\u2009=\u20092.5 [2.3\u2009\u2212\u20092.8] vs adj.ROR\u2009=\u20092.6 [2.1\u2009\u2212\u20093.3]), and fractures (adj.ROR\u2009=\u20091.7 [1.4\u2009\u2212\u20092.1] vs adj.ROR\u2009=\u20091.5 [1.02\u2009\u2212\u20092.1]) in both adults and older adults, respectively. None of these safety signals was significantly greater in older adults (P\n                      <jats:sub>interaction<\/jats:sub>\n                      threshold of 0.05). Acute kidney injury was associated with SGLT2i in adults (adj.ROR\u2009=\u20091.97 [1.85\u2009\u2212\u20092.09]) but not in older adults (adj.ROR\u2009=\u20090.71 [0.59\u2009\u2212\u20090.84]). Falls, hypotension, and syncope were not associated with SGLT2i among either adults or older adults.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this global post-marketing study, none of the adverse events was reported more frequently among older adults. Our findings provide reassurance regarding SGLT2i treatment in older adults, although careful monitoring is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-023-01743-5","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T11:22:16Z","timestamp":1674559336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (\u2265\u200975\u00a0years): a retrospective, pharmacovigilance study"],"prefix":"10.1186","volume":"22","author":[{"given":"Adam","family":"Goldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilad","family":"Twig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Cukierman-Yaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan","family":"moshkovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Pomerantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Ben-Zvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Dankner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Maor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"1743_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1743_CR2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1743_CR3","doi-asserted-by":"publisher","unstructured":"Real J, Vlacho B, Ortega E, Vall\u00e9s JA, Mata-Cases M, Castelblanco E, et al. Cardiovascular and mortality benefits of sodium\u2013glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. Cardiovasc Diabetol [Internet]. BioMed Central Ltd; 2021 [cited 2022 Aug 27];20:1\u201311. https:\/\/doi.org\/10.1186\/s12933-021-01323-5","DOI":"10.1186\/s12933-021-01323-5"},{"key":"1743_CR4","doi-asserted-by":"publisher","unstructured":"Kim YG, Han SJ, Kim DJ, Lee KW, Kim HJ. Association between sodium-glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: A real-world nationwide population-based cohort study. Cardiovasc Diabetol [Internet]. BioMed Central Ltd.; 2018 [cited 2022 Aug 27];17:1\u20139. https:\/\/doi.org\/10.1186\/s12933-018-0737-5","DOI":"10.1186\/s12933-018-0737-5"},{"key":"1743_CR5","doi-asserted-by":"publisher","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. 101056\/NEJMoa1911303 [Internet]. Massachusetts Medical Society; 2019 [cited 2022 Feb 13];381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","DOI":"10.1056\/NEJMoa1911303"},{"key":"1743_CR6","doi-asserted-by":"publisher","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med [Internet]. Massachusetts Medical Society; 2020 [cited 2022 Feb 13];383:1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190","DOI":"10.1056\/NEJMoa2022190"},{"key":"1743_CR7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385:1451\u201361.","journal-title":"N Engl J Med"},{"key":"1743_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2022.04.040","volume":"80","author":"M B\u00f6hm","year":"2022","unstructured":"B\u00f6hm M, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Abdin A, et al. Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. J Am Coll Cardiol. 2022;80:1\u201318.","journal-title":"J Am Coll Cardiol"},{"key":"1743_CR9","doi-asserted-by":"publisher","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med [Internet]. Massachusetts Medical Society; 2017 [cited 2022 Jun 27];377:644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925","DOI":"10.1056\/NEJMoa1611925"},{"key":"1743_CR10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1743_CR11","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jamainternmed.2018.3034","volume":"178","author":"HY Chang","year":"2018","unstructured":"Chang HY, Singh S, Mansour O, Baksh S, Caleb AG. Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med. 2018;178:1242\u20138.","journal-title":"JAMA Intern Med"},{"key":"1743_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjdrc-2019-000725","volume":"7","author":"GP Fadini","year":"2019","unstructured":"Fadini GP, Sarangdhar M, De Ponti F, Avogaro A, Raschi E. Pharmacovigilance assessment of the association between Fournier\u2019s gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2019;7:1\u20138.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1743_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2021.766125","volume":"12","author":"X Zhou","year":"2021","unstructured":"Zhou X, Ye X, Guo X, Liu D, Xu J, Hu F, et al. Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS. Front Pharmacol. 2021;12:1\u20139.","journal-title":"Front Pharmacol"},{"key":"1743_CR14","doi-asserted-by":"publisher","unstructured":"Mone P, Gambardella J, Lombardi A, Pansini A, De Gennaro S, Leo AL, et al. Correlation of physical and cognitive impairment in diabetic and hypertensive frail older adults. Cardiovasc Diabetol [Internet]. BioMed Central Ltd; 2022 [cited 2022 Aug 27];21:1\u20136. https:\/\/doi.org\/10.1186\/s12933-021-01442-z","DOI":"10.1186\/s12933-021-01442-z"},{"key":"1743_CR15","unstructured":"FDA Adverse Event Reporting System (FAERS) Public Dashboard | FDA [Internet]. [cited 2022 Jul 25]. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard"},{"key":"1743_CR16","doi-asserted-by":"publisher","unstructured":"Bonora BM, Raschi E, Avogaro A, Fadini GP. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. Cardiovasc Diabetol [Internet]. BioMed Central Ltd; 2021 [cited 2022 Aug 27];20:1\u20138. https:\/\/doi.org\/10.1186\/s12933-021-01243-4","DOI":"10.1186\/s12933-021-01243-4"},{"key":"1743_CR17","doi-asserted-by":"publisher","DOI":"10.5772\/50095","author":"Poluzzi E, Raschi E, Piccinni C, De F. Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS). Data Min Appl Eng Med [Internet]. InTech;","year":"2012","unstructured":"Poluzzi E, Raschi E, Piccinni C, De F. Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS). Data Min Appl Eng Med [Internet]. InTech; cited 2021 Feb 8. 2012. https:\/\/doi.org\/10.5772\/50095.","journal-title":"Available from:"},{"key":"1743_CR18","doi-asserted-by":"publisher","unstructured":"Mozzicato P. MedDRA: An overview of the medical dictionary for regulatory activities [Internet]. Pharmaceut. Med. Springer International Publishing; 2009 [cited 2020 Nov 15]. p. 65\u201375. https:\/\/doi.org\/10.1007\/BF03256752","DOI":"10.1007\/BF03256752"},{"key":"1743_CR19","doi-asserted-by":"crossref","unstructured":"Mozzicato P. Standardised MedDRA queries: Their role in signal detection. Drug Saf [Internet]. Drug Saf; 2007 [cited 2020 Nov 15]. p. 617\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/17604415\/","DOI":"10.2165\/00002018-200730070-00009"},{"key":"1743_CR20","doi-asserted-by":"publisher","unstructured":"Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini G, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis [Internet]. Elsevier B.V; 2018;28:533\u201342. https:\/\/doi.org\/10.1016\/j.numecd.2018.02.014","DOI":"10.1016\/j.numecd.2018.02.014"},{"key":"1743_CR21","doi-asserted-by":"publisher","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf [Internet]. John Wiley & Sons, Ltd; 2009;18:427\u201336. https:\/\/doi.org\/10.1002\/pds.1742","DOI":"10.1002\/pds.1742"},{"key":"1743_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"key":"1743_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, Dumouchel W, Lependu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93:539\u201346.","journal-title":"Clin Pharmacol Ther"},{"key":"1743_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57\u201369.","journal-title":"Stat Methods Med Res"},{"key":"1743_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"J Liu","year":"2017","unstructured":"Liu J, Li L, Li S, Jia P, Deng K, Chen W, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis. Sci Rep. 2017;7:1\u201311.","journal-title":"Sci Rep"},{"key":"1743_CR26","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/ageing\/afz096","volume":"48","author":"P Monteiro","year":"2019","unstructured":"Monteiro P, Bergenstal RM, Toural E, Inzucchi SE, Zinman B, Hantel S, et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME\u00ae trial. Age Ageing. 2019;48:859\u201366.","journal-title":"Age Ageing"},{"key":"1743_CR27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2337\/dc19-1476","volume":"43","author":"A Cahn","year":"2020","unstructured":"Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, et al. Efficacy and safety of dapagliflozin in the elderly: Analysis from the DECLARE-TIMI 58 study. Diabetes Care. 2020;43:468\u201375.","journal-title":"Diabetes Care"},{"key":"1743_CR28","doi-asserted-by":"crossref","unstructured":"Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med [Internet]. Ann Intern Med; 2019 [cited 2022 Jun 25];170:764\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/31060053\/","DOI":"10.7326\/M19-0085"},{"key":"1743_CR29","doi-asserted-by":"crossref","unstructured":"Dave C V., Schneeweiss S, Patorno E. Association of Sodium-Glucose Cotransporter 2 Inhibitor Treatment With Risk of Hospitalization for Fournier Gangrene Among Men. JAMA Intern Med [Internet]. American Medical Association; 2019 [cited 2022 Jun 25];179:1587\u201390. https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2749348","DOI":"10.1001\/jamainternmed.2019.2813"},{"key":"1743_CR30","doi-asserted-by":"crossref","unstructured":"Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang CE, Tereshchenko S, et al. Efficacy and Safety of Dapagliflozin in Heart Failure with Reduced Ejection Fraction According to Age: Insights from DAPA-HF. Circulation. 2020;100\u201311.","DOI":"10.1161\/CIRCULATIONAHA.119.044133"},{"key":"1743_CR31","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jacc.2021.07.050","volume":"78","author":"N Girerd","year":"2021","unstructured":"Girerd N. Low Blood Pressure and Managing Drugs in HF: Where Do SGLT2 Inhibitors Stand? J Am Coll Cardiol. 2021;78:1349\u201351.","journal-title":"J Am Coll Cardiol"},{"key":"1743_CR32","doi-asserted-by":"crossref","unstructured":"Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study. Ann Intern Med [Internet]. Ann Intern Med; 2019 [cited 2022 Jun 26];170:155\u201363. https:\/\/pubmed.ncbi.nlm.nih.gov\/30597484\/","DOI":"10.7326\/M18-0567"},{"key":"1743_CR33","doi-asserted-by":"crossref","unstructured":"Zhuo M, Hawley CE, Paik JM, Bessette LG, Wexler DJ, Kim DH, et al. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Netw open [Internet]. JAMA Netw Open; 2021 [cited 2022 Jun 26];4. https:\/\/pubmed.ncbi.nlm.nih.gov\/34705014\/","DOI":"10.1001\/jamanetworkopen.2021.30762"},{"key":"1743_CR34","doi-asserted-by":"crossref","unstructured":"Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab [Internet]. J Clin Endocrinol Metab; 2016 [cited 2022 Jun 26];101:157\u201366. https:\/\/pubmed.ncbi.nlm.nih.gov\/26580237\/","DOI":"10.1210\/jc.2015-3167"},{"key":"1743_CR35","doi-asserted-by":"crossref","unstructured":"Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial. Diabetes Care [Internet]. American Diabetes Association; 2018 [cited 2022 Jun 27];41:e4\u20135. https:\/\/diabetesjournals.org\/care\/article\/41\/1\/e4\/36630\/Empagliflozin-and-Assessment-of-Lower-Limb","DOI":"10.2337\/dc17-1551"},{"key":"1743_CR36","doi-asserted-by":"crossref","unstructured":"Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb\/III clinical trials. Diabetes Obes Metab [Internet]. Diabetes Obes Metab; 2018 [cited 2022 Jun 27];20:620\u20138. https:\/\/pubmed.ncbi.nlm.nih.gov\/28950419\/","DOI":"10.1111\/dom.13124"},{"key":"1743_CR37","doi-asserted-by":"crossref","unstructured":"Khouri C, Cracowski JL, Roustit M. SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect? Diabetes Obes Metab [Internet]. Diabetes Obes Metab; 2018 [cited 2022 Jun 27];20:1531\u20134. https:\/\/pubmed.ncbi.nlm.nih.gov\/29430814\/","DOI":"10.1111\/dom.13255"},{"key":"1743_CR38","doi-asserted-by":"publisher","unstructured":"Fadini GP, Avogaro A. SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol [Internet]. Elsevier Ltd; 2017;5:680\u20131. https:\/\/doi.org\/10.1016\/S2213-8587(17)30257-7","DOI":"10.1016\/S2213-8587(17)30257-7"},{"key":"1743_CR39","doi-asserted-by":"publisher","unstructured":"Lin C, Zhu X, Cai X, Yang W, Lv F, Nie L, et al. SGLT2 inhibitors and lower limb complications: an updated meta\u2010analysis. Cardiovasc Diabetol [Internet]. BioMed Central Ltd; 2021 [cited 2022 Aug 27];20:1\u201312. https:\/\/doi.org\/10.1186\/s12933-021-01276-9","DOI":"10.1186\/s12933-021-01276-9"},{"key":"1743_CR40","doi-asserted-by":"crossref","unstructured":"Fralick M, Kim SC, Schneeweiss S, Everett BM, Glynn RJ, Patorno E. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370.","DOI":"10.1136\/bmj.m2812"},{"key":"1743_CR41","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/dom.14075","volume":"22","author":"J Liu","year":"2020","unstructured":"Liu J, Li L, Li S, Wang Y, Qin X, Deng K, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes, Obes Metab. 2020;22:1619\u201327.","journal-title":"Diabetes, Obes Metab"},{"key":"1743_CR42","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1210\/jc.2019-00139","volume":"104","author":"PS Hamblin","year":"2019","unstructured":"Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, et al. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and during Hospital Admission. J Clin Endocrinol Metab. 2019;104:3077\u201387.","journal-title":"J Clin Endocrinol Metab"},{"key":"1743_CR43","doi-asserted-by":"publisher","unstructured":"Douros A, Lix LM, Fralick M, Dell\u2019Aniello S, Shah BR, Ronksley PE, et al. Sodium\u2013Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis: A Multicenter Cohort Study. Ann Intern Med [Internet]. American College of Physicians; 2020 [cited 2022 Jul 8];173:417\u201326. https:\/\/doi.org\/10.7326\/M20-0289","DOI":"10.7326\/M20-0289"},{"key":"1743_CR44","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","volume":"60","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia Diabetologia. 2017;60:1385\u20139.","journal-title":"Diabetologia Diabetologia"},{"key":"1743_CR45","doi-asserted-by":"publisher","unstructured":"Adamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, et al. Initial Decline (\u201cdip\u201d) in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF. Circulation [Internet]. American Heart Association; 2022;0. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.058910","DOI":"10.1161\/CIRCULATIONAHA.121.058910"},{"key":"1743_CR46","doi-asserted-by":"publisher","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, et al. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. Circulation [Internet]. American Heart Association; 2021;143:310\u201321. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051685","DOI":"10.1161\/CIRCULATIONAHA.120.051685"},{"key":"1743_CR47","doi-asserted-by":"publisher","unstructured":"Schechter M, Melzer-Cohen C, Rozenberg A, Yanuv I, Chodick G, Karasik A, et al. Cardiorenal outcomes with sodium\/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence. Cardiovasc Diabetol [Internet]. BioMed Central Ltd; 2021 [cited 2022 Aug 27];20:1\u201312. https:\/\/doi.org\/10.1186\/s12933-021-01362-y","DOI":"10.1186\/s12933-021-01362-y"},{"key":"1743_CR48","doi-asserted-by":"publisher","unstructured":"Heerspink HJL, Stef\u00e1nsson B V., Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med [Internet]. Massachusetts Medical Society; 2020 [cited 2022 Jul 23];383:1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816","DOI":"10.1056\/NEJMoa2024816"},{"key":"1743_CR49","doi-asserted-by":"crossref","unstructured":"Khouri C, Petit C, Tod M, Lepelley M, Revol B, Roustit M, et al. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. J Clin Epidemiol [Internet]. Elsevier Inc.; 2021 [cited 2021 Apr 16];134:14\u201321. https:\/\/pubmed.ncbi.nlm.nih.gov\/33508405\/","DOI":"10.1016\/j.jclinepi.2021.01.015"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01743-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01743-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01743-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T09:44:33Z","timestamp":1679478273000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01743-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1743"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01743-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"19 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because the FAERS is a publicly available and anonymized database, institutional review board approval and informed consent were waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TCY reports a research Grant from Medtronic, MSD. Honoraria for speaking from AstraZeneca, MSD, Novo Nordisk, Lilly, Medtronic, BI, Geffen medical, and Sanofi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}